e-learning
resources
Virtual 2020
Pre-Congress Content
Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: Real world experiencefrom a tertiary university hospital
S. Kim (Seoul, Republic of Korea), J. Shin (Seoul, Republic of Korea), M. Song (Seoul, Republic of Korea), M. Park (Seoul, Republic of Korea), Y. Kang (Seoul, Republic of Korea)
Source:
Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Session:
Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Session type:
E-poster session
Number:
1848
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Kim (Seoul, Republic of Korea), J. Shin (Seoul, Republic of Korea), M. Song (Seoul, Republic of Korea), M. Park (Seoul, Republic of Korea), Y. Kang (Seoul, Republic of Korea). Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: Real world experiencefrom a tertiary university hospital. 1848
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Antithrombotics in idiopathic pulmonary fibrosis patients with concomitant antifibrotic therapy: a single centre real world experience
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Real world idiopathic pulmonary fibrosis in the EMPIRE registry
Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries
Year: 2018
Pirfenidone in idiopathic pulmonary fibrosis - Real life experience from a german tertiary referral centre for interstitial lung diseases
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Clinical experience with nintedanib for IPF in 3 UK tertiary referral centres
Source: International Congress 2016 – IPF treatment II
Year: 2016
Real life patient experience of pirfenidone in a regional interstitial lung disease clinic
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Frequency of chronic pulmonary aspergillosis in patients treated for pulmonary tuberculosis at a tertiary care hospital in Karachi, Pakistan.
Source: Virtual Congress 2021 – Tuberculosis, COVID-19 and other comorbidities
Year: 2021
Mortality outcomes in patients with idiopathic pulmonary fibrosis treated with antifibrotics: a real world study
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021
Cost-effectiveness of an early supported discharge service (ESDS) for chronic obstructive pulmonary disease (COPD) in a university hospital serving a large rural population
Source: Annual Congress 2007 - Ethical and economic choices in respiratory care
Year: 2007
Idiopathic pulmonary fibrosis and systemic sclerosis-interstitial lung disease: features at admission to a tertiary pulmonology unit.
Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020
Clinical characteristics of patients with Idiopathic pulmonary fibrosis in a tertiary care center of a developing country
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
Differing clinical courses of IPF at an acute district general hospital
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Late Breaking Abstract - Effectiveness and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) from a large Italian practice cohort
Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias
Year: 2018
Acute exacerbation of ILD: an Indian tertiary centre experience
Source: International Congress 2018 – Clinical aspects of hypersensitivity pneumonitis (HP) and CTD-ILD: diagnosis, monitoring and treatment
Year: 2018
Effects of programed education for chronic obstructive pulmonary disease on tertiary teaching hospital
Source: International Congress 2019 – Medical education
Year: 2019
Costs of the patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease in a tertiary university hospital of Turkey
Source: International Congress 2015 – COPD: chronic disease and comorbidities
Year: 2015
Interstitial lung disease at a district general hospital: When are patients referred to tertiary care?
Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia
Year: 2019
Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry
Source: Eur Respir J 2015; 46: 186-196
Year: 2015
PROOF: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting in Belgium and Luxembourg: Exposure in the interim report of 175 IPF patients
Source: International Congress 2016 – IPF clinical
Year: 2016
Clinical profile of pulmonary hypertension at a tertiary care centre, India
Source: International Congress 2017 – Imaging and lung disease PH
Year: 2017
Incidence of idiopathic pulmonary fibrosis in Italy. Analysis of hospital admission and mortality databases of a large Italian region
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept